Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy
For information about trials that are currently recruiting patients, please visit www.clinicaltrials.gov.
This press release contains "forward-looking" statements, including statements regarding the conduct of clinical trials of DV281 and SD-101. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether we can timely provide adequate clinical supplies; initiation, enrollment and completion of clinical trials of DV281 and SD-101; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; the ability to successfully develop and commercialize DV281 and SD-101; and whether or not
News Provided by Acquire Media